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Stem cells and progenitor cells in renal tissue. Stem cells and
progenitor cells are necessary for repair and regeneration of
injured renal tissue. Infiltrating or resident stem cells can con-
tribute to the replacement of lost or damaged tissue. However,
the regulation of circulating progenitor cells is not well un-
derstood. We have analyzed the effects of erythropoietin on
circulating progenitor cells and found that low levels of erythro-
poietin induce mobilization and differentiation of endothelial
progenitor cells. In an animal model of 5/6 nephrectomy we
could demonstrate that erythropoietin ameliorates tissue injury.
Full regeneration of renal tissue demands the existence of stem
cells and an adequate local “milieu,” a so-called stem cell niche.
We have previously described a stem cell niche in the kidneys of
the dogfish, Squalus acanthus. Further analysis revealed that in
the regenerating zone of the shark kidney, stem cells exist that
can be induced by loss of renal tissue to form new glomeruli.
Such animal models improve our understanding of stem cell
behavior in the kidney and may eventually contribute to novel
therapies.
The kidney is a delicately structured organ with a com-
plex interacting network of arterioles, capillaries, tubules
formed by epithelial cells, neuronal cells, and lymphatic
vessels. These structural components are arranged in a
complex three-dimensional architecture to allow the reg-
ulated flow of blood into and out of the kidney, the filter-
ing of large amounts of fluid, and finally, the readsorption
of this fluid back into the body. In addition, the renal struc-
tures and cells participate in the regulation of the whole
body by sensing and responding to signals from outside.
It is obvious that regeneration after injury of such a com-
plicated structure, even parts of it, has been considered to
be impossible. Renal cells, such as podocytes or endothe-
lial cells, seem to be terminally differentiated and their
loss by apoptosis or necrosis leads to loss of organ func-
tion and renal disease. However, for a long time it has
been obvious that the cells lining the renal tubules can
regenerate. After injury and loss of epithelial cells which
leads to acute renal failure, tubular function reappears
in most cases and tubular cells are replaced. In addition,
at least in animal models, complete loss of glomerular
structure (i.e., in the so-called Thy 1 glomerulonephritis),
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the glomeruli may heal and reappear after the immuno-
logic injury. We also know that extensive cell prolifera-
tion such as in rapid progressive glomerulonephritis may
eventually heal and glomeruli recover from severe struc-
tural damage. An open question is to the mechanisms
of cellular repair and regeneration in the kidney after
injury. In general, two major mechanisms may be dis-
cussed in repair and regeneration. The first mechanism
is repair after (limited) injury to the kidney. Following
death of renal cells after ischemia or toxic damage these
cells may be replaced by either (1) neighboring cells or
(2) infiltrating cells most likely from the blood stream.
An implicit assumption for such a repair process is the
still existing integrity of the local “milieu” (i.e., structures
such as basement membrane or other matrix components,
neighboring cell membranes, and locally produced “fac-
tors”) guarantee appropriate differentiation and prolif-
eration of these “repair” cells. Lately, the possible role
of “stem cells” in these repair processes has been ad-
dressed by several investigators. The second mechanism
is regeneration of lost tissue. Regeneration assumes that
complete structures of the kidney can be replaced. In its
purest form regenerated tissue may come from stem cells
which are capable of generating glomerular and tubular
structures by an inborn program. As in the embryonic
development these cells may be of mesenchymal origin
and need appropriate stimulation for nephrogenesis. In
mammals, nephrogenesis in the adult organ has not been
observed so far; however, in amphibiae, formation of new
nephrons in the adult animal is not a rare phenomenon.
Recently, cells with a stem-like behavior have been de-
scribed in mammalian kidneys; however, their function is
yet unclear.
We have investigated both mechanisms of vascular re-
pair by progenitor cells and renal regeneration during
the last years. We will present an overview of our results
and outline future research strategies. It is necessary to
point out that mechanisms of repair and regeneration
have to be discussed on the background of the respec-
tive model of injury. It seems obvious that different types
of injury induce different signals which may or may not
lead to the induction of repair and regeneration. Also
the time course of the injury and the time of therapeutic
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intervention may be of importance (i.e., stem cells or pro-
genitor cells may have a “time window” when they exert
their beneficial effects) [1].
CIRCULATING PROGENITOR CELLS
Progenitor cells have emerged as a new exciting thera-
peutic option for a variety of conditions in cardiovascular
medicine such as myocardial infarction, heart failure, and
peripheral vascular disease. The encouraging results from
recent experimental and animal studies are currently be-
ing tested in several clinical trials, focusing mainly on the
treatment of patients with acute myocardial infarction
and/or heart failure [2–5]. For this purpose, mostly bone
marrow–derived mononuclear cells (BMCs) have been
obtained directly from the patient’s bone marrow by as-
piration and eventually expanded ex vivo before intra-
coronary or even intravenous application. The majority
of these rather small studies primarily explored the feasi-
bility and safety of this experimental approach. In the first
randomized controlled trial from the Department of In-
ternal Medicine of the Hannover Medical School, several
parameters of cardiac function were assessed in patients
who received intracoronary BMCs after acute myocar-
dial infarction [6]. The preliminary results are positive
and will certainly boost the enthusiasm of the cardiovas-
cular community for large-scale studies. Of even greater
importance than stem cell therapy of acute myocardial
dysfunction could be the prevention of progression of
chronic atherosclerotic vascular disease and is associated
syndromes. In this respect, BMCs seem less useful than
circulating progenitor cells, because the latter can be,
at least theoretically, persistently stimulated in vivo by
targeted pharmacologic interventions. Endothelial pro-
genitor cells (EPCs) have come into focus in cardiovas-
cular research recently because they are thought to be
responsible for endothelial and, hence, vascular repair
[7, 8]. This has been investigated extensively in experi-
mental studies using different animal models of cardio-
vascular injury and repair [9–11]. EPCs circulate in the
vasculature, where they home and incorporate into sites
of active neovascularization [12, 13]. In fact, EPCs or-
chestrate re-endothelialization of damaged vessel walls,
also by secreting a large number of important cytokines
which attract and govern cells that are indispensable in
the process of endothelial repair [14, 15]. Data obtained
in human studies are even more intriguing; in patients
with coronary artery disease, the number of EPCs corre-
lates strongly with the number of cardiovascular risk fac-
tors, and this correlation exists even in apparently healthy
subjects without manifest atherosclerosis [16, 17]. In the
latter population, the number of EPCs also correlates sig-
nificantly with the degree of endothelial dysfunction [17].
Furthermore, in clinical conditions known to be associ-
ated with increased cardiovascular risk, such as diabetes
mellitus, the number and/or function of EPCs is dimin-
ished [18].
EPCs are considered to originate from CD34+
hematopoietic stem cells (HSCs), which differentiate via
separate pathways into erythrocytes, thrombocytes, var-
ious lineages of leukocytes and endothelial cells. These
mononuclear cells can be analyzed in patient’s peripheral
blood by flow cytometry using different stem cell surface
marker proteins such as CD34 and CD133, as well as their
morphologic qualities [19]. In contrast, flow cytometry
of EPCs is still plagued by technical difficulties, partly
because of their very small number in the peripheral
circulation which hampers their identification and sub-
division. Due to their adhesion on culture plates, EPCs
can be isolated from the peripheral blood mononuclear
cell fraction, however, and can be identified further in cul-
ture by different endothelial cell marker characteristics
[7, 8].
Renal patients are characterized by extremely high
cardiovascular morbidity and mortality, and most die of
complications related to atherosclerosis, namely, myocar-
dial infarction and stroke [20]. Numerous cardiovascular
risk factors are thought to play a role, but the idea that
impaired vascular repair mechanisms as a result of re-
duced number and/or impaired function of EPCs may
contribute to the problem has not been pursued so far.
We could demonstrate recently that the number of EPCs
in peripheral blood is indeed significantly reduced in
patients with advanced renal failure as compared with
age- and gender-matched healthy subjects [21]. A similar
observation has been made in patients on maintenance
haemodialysis [22, 23]. We also found a significant corre-
lation between CD34+ HPCs and EPCs in renal patients,
a finding that points to a problem of differentiation of
precursor cells to EPCs or to reduced mobilization of
EPCs from the bone marrow, or both, in uremia. The for-
mer assumption is supported further by the observation
of a significant inhibitory effect of uremic serum on the
differentiation capacity of EPCs in vitro [21]. Moreover,
their capability to migrate and to form tube-like (vascu-
lar) structures in vitro is also reduced. One important
factor contributing to EPC deficiency in patients with
advanced renal failure could be lack of erythropoietin
(EPO). In the above-mentioned studies we have found
that plasma EPO levels were an independent predictor
of EPC levels in renal patients (not published). Taken
together, in patients with renal failure, EPC differentia-
tion is hampered and may lead to malfunction of vascu-
lar repair mechanisms. This finding is reminiscent of the
well-known defects of cellular function caused by uremic
intoxication [24].
The finding that the number of functionally active
EPCs in peripheral blood can be modulated by increas-
ing their proliferation and/or release from the bone
marrow could be of overriding therapeutic importance.
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Experimental work and studies in humans have revealed
that the number of EPCs in peripheral blood can be in-
creased by pharmacologic interventions such as adminis-
tration of statins [25] or angiotensin II receptor blockers.
Moreover, the demonstration that recombinant human
EPO (rhEPO) or its analogue darbepoetin is a powerful
stimulatory agent for EPC proliferation and functional
activity is of particular interest for the nephrological com-
munity [26–29]. A marked and persistent stimulation of
EPC recruitment in vitro and in vivo was demonstra-
ble even at subtherapeutic rhEPO doses with respect to
treatment of renal anemia [28]. In parallel with the im-
provement of cellular function (e.g., tube-like formation
activity), rhEPO directly activates the Akt tyrosine ki-
nase signaling pathway in EPCs [27, 29]. The stimulation
of this important prosurvival cellular pathway may ren-
der EPCs more resistant against an ischemic milieu, as has
been demonstrated recently for mesenchymal stem cells
genetically enhanced with Akt1 (i.e., the gene encoding
Akt) [30].
Thus, stimulation of EPCs by administration of statins
and/or rhEPO or analogues could be a new promis-
ing therapeutic strategy in regenerative cardiovascular
medicine in order to prevent the sequelae of atheroscle-
rotic vascular disease. This approach may also be useful
in patients with renal failure, a population at particularly
high cardiovascular risk. In this respect, administration
of statins and/or rhEPO might be indicated at an earlier
stage of renal failure than currently recommended.
REGENERATION OF RENAL TISSUE
The capacity of the kidney to regenerate and repair
is limited and has only been convincingly shown in is-
chemic tubular necrosis. After toxic or ischemic injury to
tubular epithelial cells there is cellular proliferation and
functional recovery [31]. The origin of newly generated
renal cells is largely undefined, but some cells appear to
derive from division of fully differentiated cells [32], and
recent work has shown that bone marrow cells could re-
populate the nephron after ischemia [33]. In addition, by
analogy with other organs, it may also possible that new
regenerating cells also derive from organ-specific pluripo-
tent cells (i.e., adult renal stem cells). Organ-specific stem
cells were initially recognized in the hematopoietic sys-
tem, skin, and intestinal epithelia, where self-renewal is
manifestly apparent, but they are also present in organs
that do not have rapid rates of cell turnover, such as the
nervous system, prostate, liver, etc. Although the num-
ber of organs known to harbor adult stem cells continues
to grow, it remains unknown whether the adult kidney
possesses stem cells among its many cell types.
In a recent study it has been shown that the renal adult
papilla contains large numbers of slowly cycling cells that
persist throughout the life of the animal but quickly en-
ter the cell cycle and disappear from the papilla during
recovery from a transient episode of ischemia, suggest-
ing that these cells participate in renal repair [34]. The
disappearance of the cells from the papilla could not be
explained by their death in response to ischemia; apop-
tosis was absent from the papilla but was abundant in
other renal regions after ischemia. This suggests that, as in
other organs [35], proliferating cells may migrate toward
the site of maximal injury (i.e., the medulla). In addition,
in the same study was shown that renal papillary cells
grown in vitro were capable of incorporating into other
parts of the renal parenchyma, including renal tubules.
Isolation and in vitro culture of papillary cells allowed
derivation of clones capable of generating more than one
cell type, which, like metanephric mesenchymal stem cells
[36], showed remarkable plasticity and coexpressed ep-
ithelial and mesenchymal markers. Furthermore, the cells
were capable of forming spheres, a characteristic of many
organ-specific adult stem cells in vitro. As an aggregate,
these data indicate that adult kidney stem cells may reside
in the papilla.
In contrast to these first observations and character-
izations of resident stem cells in mammalian tissue re-
generation of renal tissue in marine animals has been
observed on several occasions. Marlies Elger and oth-
ers have recently characterized a nephrogenic zone in
the adult kidneys from the skate and the shark [37]. In
contrast to mammalians where nephrogenesis seems to
stop several days after birth the kidneys in shark and
skate are able to form new glomeruli throughout life. It
seems that the place where new glomeruli can be formed
is spatially restricted and resides in the outer layers of the
shark kidneys. During the formation of new glomeruli
these are gradually transported into areas of adult renal
tissue. The area where new glomeruli have grown has
been termed the “nephrogenic zone.” This nephrogenic
zone represents a niche within the kidney where stem cell-
like cells reside. The nephrogenic zone of the skate con-
tains the essential structures characteristically found in
the embryonic mammalian metanephros. We defined four
stages of nephron development. The evaluation of the
four stages in the adult skate corroborated previous light
and electron microscopic results in the European dog-
fish, Scyliorhinus caniculus [38]. Because certain stages
of nephrogenesis have been observed in adult specimen
of several other fish species, neonephrogenesis is prob-
ably a common feature in elasmobranchs and teleosts.
Mesenchymal cells capable of nephrogenesis must es-
tablish contact with collecting duct tips for growth and
branching to occur [39]. It can be anticipated that mes-
enchymal cells competent for nephron development pre-
sumably provide the progenitor cells also in the skate.
These cells are presumably derived from a continuous
pool of embryonic stem cell-like cells within the nephro-
genic zone of the elasmobranch kidney. We suggest
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that these cells are precursors of competent stage I
mesenchyme. We further suggest that the mesenchyme
provides self-renewing cells for ongoing nephrogenesis.
Such cells would fulfill requirements of stem cells. Fu-
ture studies involving lineage studies will address these
hypotheses.
We could also demonstrate in a recent study that renal
tissue in the nephrogenic zone responds to partial reduc-
tion of renal mass with the formation of new nephrons.
In this study, we were able to confirm our earlier find-
ings that neonephrogenesis indeed occurs in the adult
elasmobranch [37]. Our new observations of 5-bromo-
2′-deoxyuridine (BrdU) incorporation in skate provide
further evidence for formation of nephrons de novo in
the nephrogenic zone. Mitotic activity as visualized by
this technique was high in various stages of nephron
development and young nephrons of nephrectomized
animals. Older portions of the kidney were virtually de-
void of BrdU labeling. Similar results were obtained in
the remnant portion of the operated kidney. This clearly
shows that it is only the lateral zone that can be stimu-
lated to substantial renal regeneration with production
of new nephrons. In this region, nephron development
and growth of the collecting duct system together with
growth of the renal vasculature can be stimulated. We
suggest that the undifferentiated cells residing in the
mesenchyme of the lateral kidney zone can provide tar-
gets for signals that initiate cell division after stimulation
by nephrectomy. This will be followed by the formation
of initial stages of nephron development. The formation
of new nephrons was also observed in adult teleosts. The
reasons for loss of this ability in higher vertebrates are un-
clear. During prenatal growth of the metanephric mam-
malian kidney, nephrogenesis can be greatly augmented
according to recent uninephrectomy experiments with
unborn sheep [34]. In these animals, compensatory re-
nal growth of the contralateral kidney is associated with
an increase in final nephron number due to prolonged
nephrogenic growth in the embryonic metanephros.
Our experiments suggest that the elasmobranch kidney
is equipped with a nephrogenic zone, in which simi-
lar “embryonic growth” persists life-long. The nephro-
genic potential can be activated by removal of renal
tissue.
We believe that our findings have exciting perspectives.
We provide a model in which new nephron production
can be observed. We believe that identifying the stem
cells capable of nephrogenesis in this model is possible.
Their identification will facilitate studying the signaling
molecules responsible. Gene expression studies should
be helpful in this regard. Because teleost fish also possess
nephrogenic potential, our studies may be transferable
to zebrafish, the genome of which is currently available.
However, elucidation of the elasmobranch genome also
stands on the horizon. We suggest that models such as
these will improve our understanding of basic functions
and eventually will contribute to novel therapies.
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